This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
このページの翻訳は実験的なもので、現在 開発中です。お待ちしております！
Biofrontera 過去の業績
過去 基準チェック /36
主要情報
32.4%
収益成長率
41.1%
EPS成長率
| Pharmaceuticals 業界の成長 | 7.3% |
| 収益成長率 | 17.6% |
| 株主資本利益率 | 28.1% |
| ネット・マージン | 33.9% |
| 前回の決算情報 | 30 Jun 2022 |
最近の業績更新
Recent updates
収支内訳
収支内訳
Biofrontera の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 22 | 31 | 10 | 24 | 7 |
| 31 Mar 22 | 30 | 15 | 29 | 7 |
| 31 Dec 21 | 29 | 38 | 34 | 7 |
| 30 Sep 21 | 28 | -16 | 28 | 6 |
| 30 Jun 21 | 27 | -16 | 29 | 5 |
| 31 Mar 21 | 29 | -12 | 26 | 5 |
| 31 Dec 20 | 30 | -13 | 28 | 5 |
| 30 Sep 20 | 33 | -17 | 33 | 5 |
| 30 Jun 20 | 33 | -22 | 37 | 5 |
| 31 Mar 20 | 31 | -10 | 45 | 5 |
| 31 Dec 19 | 31 | -7 | 44 | 5 |
| 30 Sep 19 | 26 | 1 | 44 | 4 |
| 30 Jun 19 | 26 | 8 | 40 | 5 |
| 31 Mar 19 | 23 | -8 | 33 | 5 |
| 31 Dec 18 | 21 | -9 | 31 | 4 |
| 30 Sep 18 | 19 | -14 | 24 | 4 |
| 30 Jun 18 | 16 | -15 | 22 | 4 |
| 31 Mar 18 | 14 | -16 | 21 | 4 |
| 31 Dec 17 | 12 | -16 | 20 | 4 |
| 30 Sep 17 | 11 | -18 | 21 | 5 |
| 30 Jun 17 | 9 | -16 | 17 | 5 |
| 31 Mar 17 | 8 | -14 | 14 | 5 |
| 31 Dec 16 | 6 | -11 | 12 | 5 |
| 30 Sep 16 | 4 | -9 | 9 | 4 |
| 30 Jun 16 | 4 | -7 | 8 | 4 |
| 31 Mar 16 | 4 | -9 | 7 | 6 |
| 31 Dec 15 | 4 | -11 | 7 | 6 |
| 30 Sep 15 | 4 | -12 | 7 | 7 |
質の高い収益: B8FE has a large one-off gain of €39.7M impacting its June 30 2022 financial results.
利益率の向上: B8FE became profitable in the past.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: B8FE has become profitable over the past 5 years, growing earnings by 32.4% per year.
成長の加速: B8FE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
収益対業界: B8FE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.2%).
株主資本利益率
高いROE: B8FE's Return on Equity (28.1%) is considered high.